Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials

Abstract Traditionally, phase II single-arm trials are based on a binary response variable that represents the efficacy of the experimental treatment. However, the introduction of an additional binary endpoint to assess whether the new therapy is also sufficiently safe for a further evaluation in larger phase III studies is often suggested. A Bayesian predictive strategy for interim monitoring in phase II trials focused on bivariate binary outcomes is proposed. At any interim analysis, the stopping rules are based on the evaluation of the predictive probability that the trial will show a conclusive result at the planned end of the study, given the observed data. The proposed procedure is applied using hypothetical scenarios that represent different situations which may occur at the interim stage. A real data application is also illustrated with the use of both non-informative and informative prior distributions. Finally, simulation studies to evaluate the operating characteristics of the design have been performed.

[1]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[2]  Anastasios A Tsiatis,et al.  Adaptive two‐stage designs in phase II clinical trials , 2006, Statistics in medicine.

[3]  David Machin,et al.  Bayesian two‐stage designs for phase II clinical trials , 2002, Statistics in medicine.

[4]  M R Conaway,et al.  Designs for phase II trials allowing for a trade-off between response and toxicity. , 1996, Biometrics.

[5]  Nan Chen,et al.  Phase II trial design with Bayesian adaptive randomization and predictive probability , 2012, Journal of the Royal Statistical Society. Series C, Applied statistics.

[6]  Ming-Dauh Wang,et al.  Bayesian predictive approach to interim monitoring in clinical trials , 2006, Statistics in medicine.

[7]  P Brutti,et al.  An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials. , 2011, Statistics in medicine.

[8]  P. Thall,et al.  Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.

[9]  Peter F. Thall,et al.  Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. , 1998 .

[10]  D. Spiegelhalter,et al.  Bayesian Approaches to Clinical Trials and Health-Care Evaluation: Spiegelhalter/Clinical Trials and Health-Care Evaluation , 2004 .

[11]  J Jack Lee,et al.  A predictive probability design for phase II cancer clinical trials , 2008, Clinical trials.

[12]  Guosheng Yin,et al.  Clinical Trial Design: Bayesian and Frequentist Adaptive Methods , 2011 .

[13]  Ying Yuan,et al.  BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints , 2017, Statistics in medicine.

[14]  Hua Jin,et al.  A design of phase II cancer trials using total and complete response endpoints , 2005, Statistics in medicine.

[15]  P F Thall,et al.  New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Sarah Zohar,et al.  An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety , 2015, Statistics in medicine.

[17]  P F Thall,et al.  Practical Bayesian guidelines for phase IIB clinical trials. , 1994, Biometrics.

[18]  S. Sacchi,et al.  Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi , 2016, Haematologica.

[19]  Designs Based on Toxicity and Response , 2012 .

[20]  M R Conaway,et al.  Bivariate sequential designs for phase II trials. , 1995, Biometrics.

[21]  Bernard Asselain,et al.  Methods of joint evaluation of efficacy and toxicity in phase II clinical trials. , 2007, Contemporary clinical trials.

[22]  J. Bryant,et al.  Incorporating toxicity considerations into the design of two-stage phase II clinical trials. , 1995, Biometrics.

[23]  Valeria Sambucini,et al.  A Bayesian predictive two‐stage design for phase II clinical trials , 2008, Statistics in medicine.

[24]  W. Shih,et al.  A Bayesian–frequentist two‐stage single‐arm phase II clinical trial design , 2012, Statistics in medicine.

[25]  J Whitehead,et al.  Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes , 1999, Biometrics.

[26]  G. Yin,et al.  Bayesian Two-Stage Design for Phase II Clinical Trials with Switching Hypothesis Tests , 2017 .

[27]  T. Chen,et al.  Optimal three-stage designs for phase II cancer clinical trials. , 1997, Statistics in medicine.

[28]  Weichung J Shih,et al.  Adaptive Two‐Stage Designs for Single‐Arm Phase IIA Cancer Clinical Trials , 2004, Biometrics.

[29]  D. Spiegelhalter Incorporating Bayesian Ideas into Health-Care Evaluation , 2004 .